These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 12482197

  • 1. Effect of halofuginone on the development of tight skin (TSK) syndrome.
    McGaha T, Kodera T, Phelps R, Spiera H, Pines M, Bona C.
    Autoimmunity; 2002 Jul; 35(4):277-82. PubMed ID: 12482197
    [Abstract] [Full Text] [Related]

  • 2. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma.
    Pines M, Snyder D, Yarkoni S, Nagler A.
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):417-25. PubMed ID: 12869955
    [Abstract] [Full Text] [Related]

  • 3. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone.
    Pines M, Domb A, Ohana M, Inbar J, Genina O, Alexiev R, Nagler A.
    Biochem Pharmacol; 2001 Nov 01; 62(9):1221-7. PubMed ID: 11705455
    [Abstract] [Full Text] [Related]

  • 4. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
    McGaha TL, Phelps RG, Spiera H, Bona C.
    J Invest Dermatol; 2002 Mar 01; 118(3):461-70. PubMed ID: 11874485
    [Abstract] [Full Text] [Related]

  • 5. Analysis of the effect of halofuginone on bleomycin-induced scleroderma.
    Yamamoto T, Nishioka K.
    Rheumatology (Oxford); 2002 May 01; 41(5):594-6. PubMed ID: 12011392
    [No Abstract] [Full Text] [Related]

  • 6. Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism.
    McGaha TL, Kodera T, Spiera H, Stan AC, Pines M, Bona CA.
    Arthritis Rheum; 2002 Oct 01; 46(10):2748-61. PubMed ID: 12384935
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone.
    Levi-Schaffer F, Nagler A, Slavin S, Knopov V, Pines M.
    J Invest Dermatol; 1996 Jan 01; 106(1):84-8. PubMed ID: 8592087
    [Abstract] [Full Text] [Related]

  • 8. Halofuginone: a novel antifibrotic therapy.
    Pines M, Nagler A.
    Gen Pharmacol; 1998 Apr 01; 30(4):445-50. PubMed ID: 9522159
    [Abstract] [Full Text] [Related]

  • 9. Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis.
    Nagler A, Pines M.
    Transplantation; 1999 Dec 15; 68(11):1806-9. PubMed ID: 10609960
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone.
    Halevy O, Genin O, Barzilai-Tutsch H, Pima Y, Levi O, Moshe I, Pines M.
    Histol Histopathol; 2013 Feb 15; 28(2):211-26. PubMed ID: 23275304
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Halofuginone prevents subglottic stenosis in a canine model.
    Eliashar R, Ochana M, Maly B, Pines M, Sichel JY, Nagler A.
    Ann Otol Rhinol Laryngol; 2006 May 15; 115(5):382-6. PubMed ID: 16739671
    [Abstract] [Full Text] [Related]

  • 16. Transforming growth factor-beta 1 and collagen gene expression during postnatal skin development and fibrosis in the tight-skin mouse.
    Pablos JL, Everett ET, Harley R, LeRoy EC, Norris JS.
    Lab Invest; 1995 Jun 15; 72(6):670-8. PubMed ID: 7783425
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone.
    Halevy O, Nagler A, Levi-Schaffer F, Genina O, Pines M.
    Biochem Pharmacol; 1996 Oct 11; 52(7):1057-63. PubMed ID: 8831725
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma.
    Ong C, Wong C, Roberts CR, Teh HS, Jirik FR.
    Eur J Immunol; 1998 Sep 11; 28(9):2619-29. PubMed ID: 9754550
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.